Skip to content

May 1, 2026

Home
Signal News
Biopharma Brief
Week in Review
Contact

Light/Dark Button

Search for:

Home
Market Access
Where Gross-to-net Pressure Actually Lives After Launch

Market Access

Where Gross-to-net Pressure Actually Lives After Launch

Drug Channels

Today's guest post comes from Cindy Baksh, Chief Product Officer at ConnectiveRx.

Read full story

pharminent May 1, 2026 (Last updated: May 1, 2026)

Drug Channels

Today’s guest post comes from Cindy Baksh, Chief Product Officer at ConnectiveRx.

Read full story

Post navigation

Previous: Two biotechs raise a combined $556M in latest spurt of IPOs

Next: BMS brings the buzz around late-stage readouts amid a so-so Q1

Related Stories

Market Access

Flash Brief: PBM Reform Collides with MFN Pricing as Midterm Politics Reshape the Drug Pricing Landscape

pharminent April 29, 2026

Market Access

CMS Extends Medicare’s Short-Term Bridge Program for GLP-1 Obesity Drug Coverage

pharminent April 23, 2026

Market Access

Medicare weight loss drug pilot on ice as insurers decline to contribute

pharminent April 22, 2026

You May Have Missed

Manufacturing

Novartis unveils North Carolina API plant as final piece of $23B US expansion

pharminent May 1, 2026

Pipeline

Amgen positions MariTide as potential ‘best monthly’ obesity drug

pharminent May 1, 2026

Regulatory

FDA’s ODAC delivers one loss, one win for AstraZeneca

pharminent May 1, 2026

Regulatory

Axsome receives FDA approval for Auvelity to treat Alzheimer’s agitation

pharminent May 1, 2026

Copyright © 2026 All rights reserved. | ReviewNews by AF themes.